DBV Technologies S.A.
DBVT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001613780
In the last 90 days, DBV Technologies S.A. insiders filed 0 open-market purchases and 1 sale; 78 institutions reported holding it in 13F filings for Q2 2026, worth $345.7M in total; Duquesne Family Office is the only superinvestor holding it.
Other share classesDBVTF
Q1 2023 vs. Q4 2022
How the institutions holding DBV Technologies S.A. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 38 | 34 | −4 |
| Shares | 44.4M | 42.2M | −2.20M (−5.0%) |
| Value | $68.0M | $71.3M | +$3.35M (+4.9%) |
New holders (1)
Institutions that held DBV Technologies S.A. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Old Mission Capital LLC | 30,597 | $51.7K | 0.00% |
Sold out (5)
Institutions that held DBV Technologies S.A. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Ra Capital Management, L.P. | 1,958,957 | $3.00M |
| Optiver Holding B.V. | 104,599 | $160.0K |
| Jane Street Group, LLC | 35,010 | $53.6K |
| Two Sigma Investments, LP | 13,625 | $20.8K |
| Citigroup Inc | 65 | $99 |